Un-Audited Financial Results along with Limited Review Report thereon for the Quarter and half year ended on 30th September, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hemo Organic Limited reported unaudited results for Q2 FY26 and H1 FY26, showing a near-total collapse in business activity. Revenue from operations was just Rs. 0.01 lakh in Q2 FY26 (vs Rs. 0.19 lakh in Q2 FY25) and Rs. 0.19 lakh for the half year, compared to a full-year FY25 revenue of Rs. 241.43 lakhs — a dramatic decline. The company posted a loss after tax of Rs. 3.09 lakhs in Q2 FY26 and a loss of around Rs. 8.58 lakhs for H1 FY26, against a profit of Rs. 17.91 lakhs in H1 FY25. The balance sheet shows negative net worth, with accumulated losses of Rs. 373.39 lakhs wiping out the Rs. 346.59 lakh share capital, and cash from operations was negative at Rs. 16.81 lakhs. The auditor issued a qualified review report citing absence of balance confirmations for trade receivables and payables. Related party transactions are significant, including a Rs. 123.23 lakh loan from Managing Director Vishwambhar Singh.
The company is in severe financial distress with negative net worth, negligible revenue, continuous losses, and negative operating cash flows, raising serious going-concern questions. The qualified audit opinion and large related-party loans add to the risk profile — this is a high-risk stock that likely needs major restructuring or capital infusion for survival.